05:00 AM EST, 02/26/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) reported late Tuesday a Q4 net loss of $0.09 per diluted share, narrowing from a $0.72 loss a year earlier.

Analysts polled by FactSet expected a loss per share of $0.26.

Revenue for the quarter ended Dec. 31 was $71.4 million, compared with $13.5 million a year earlier.

Analysts polled by FactSet expected $60.8 million.

The company's shares were up 9.6% in recent premarket activity Wednesday.